Subsequently, several meta-analyses have defined the efficacy and safety of PDE5-Is alone or in combination with α1-blockers for the treatment of BPH-LUTS with or without ED [6, 7]. The gene discussed is PDE5A; the disease is benign prostatic hyperplasia.